STOCK TITAN

Precision Optics Stock Price, News & Analysis

POCI Nasdaq

Welcome to our dedicated page for Precision Optics news (Ticker: POCI), a resource for investors and traders seeking the latest updates and insights on Precision Optics stock.

Precision Optics Corporation (POCI) delivers cutting-edge optical solutions for medical, defense, and industrial applications. This news hub provides investors and industry professionals with essential updates on the company's strategic initiatives and market position.

Access official press releases, SEC filings, and operational announcements in one centralized location. Track developments across key areas including endoscopic imaging innovations, defense contract awards, and manufacturing capacity expansions. The repository includes earnings disclosures, regulatory updates, and partnership announcements critical for informed analysis.

Content is organized to highlight POCI's engineering advancements and quality-certified production processes. Users will find updates on the Unity Imaging Platform's clinical applications, custom optical device deployments, and compliance with medical device regulations.

Bookmark this page for streamlined access to Precision Optics' verified corporate communications. Combine regular monitoring with review of annual reports and investor presentations for complete market intelligence.

Rhea-AI Summary

Precision Optics (NASDAQ: POCI) has announced a registered direct offering of 1,272,500 shares of common stock at $4.00 per share, expected to generate gross proceeds of approximately $5.1 million and net proceeds of about $5.0 million after expenses.

The offering, led by existing stockholders, is scheduled to close around February 21, 2025. The company plans to use the proceeds to repay certain debts, expand facilities to support growth, and for general working capital purposes. The offering is being conducted through an effective shelf registration statement on Form S-3 previously filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.91%
Tags
-
Rhea-AI Summary

Precision Optics (NASDAQ: POCI) reported Q2 FY2025 results with revenue of $4.5 million, down from $4.8 million year-over-year but up 8% sequentially. Production revenue increased 42% sequentially to $3.3 million, while engineering revenue decreased to $1.2 million. The company reported a net loss of $1.0 million and adjusted EBITDA of -$0.6 million.

Gross margins declined to 23.6% from 30.1% in the same quarter last year. Notable developments include the January 2025 launch of the Unity Imaging Platform for endoscopic imaging devices, and receipt of a $340,000 production order for ophthalmic endoscopes. The company is accelerating deliveries against a $9 million order for urological endoscope imaging assemblies, with expected deliveries of $2.7 million in fiscal year 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
-
Rhea-AI Summary

Precision Optics (Nasdaq: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has scheduled a conference call to discuss its second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET.

The company will release its financial results and file its 10-Q after market close on the same day. Interested parties can join via phone at (844) 735-3662 or (412) 317-5705, or through a live webcast at https://app.webinar.net/z0E94DknxQO. A seven-day replay will be available through phone and webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
conferences earnings
Rhea-AI Summary

Precision Optics (Nasdaq: POCI) has launched the Unity Imaging Platform, a standardized CMOS endoscopic system with customization options for medical, industrial, and defense applications. The platform represents a significant shift from traditional custom-built solutions, offering a modular architecture suitable for both reusable and single-use endoscopic systems.

The Unity platform aims to transform endoscopic imaging device development by reducing costs, development time, and project risks through pre-validated design elements and proven architectures. Key benefits include accelerated time to market, cost efficiency, risk mitigation, and scalability for product portfolios.

The company currently has two single-use endoscope programs in production, with more in development. Future platform expansions will include advanced capabilities such as multi-sensor imaging for 3D and fluorescence applications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
-
Rhea-AI Summary

Precision Optics (POCI) has received a $340,000 initial production order for a new single-use ophthalmic endoscope from a major global medical device company. Production will start in January 2025, with delivery over five months to support a June 2025 product launch. Follow-on orders are expected at 2-3x the initial rate. This represents the second single-use program moving to production this year, following a $9 million cystoscope imaging assembly order. The new product replaces an existing reusable endoscope system with improved image quality and single-use functionality.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
none
-
Rhea-AI Summary

Precision Optics (NASDAQ: POCI) reported Q1 FY2025 financial results with revenue of $4.2 million, slightly down from $4.3 million in Q1 FY2024. The company experienced decreased gross margins of 26.6% compared to 33.9% year-over-year, and reported a net loss of $1.3 million. Engineering revenue remained stable at $1.9 million, while production revenue slightly decreased to $2.3 million. Notable developments include accelerated production deliveries for a $9 million urological endoscope order and a new $340,000 production order for single-use ophthalmic endoscopes, with expectations of substantial revenue growth in Q2 FY2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
Rhea-AI Summary

Precision Optics (Nasdaq: POCI), a designer and manufacturer of advanced optical instruments for medical and defense/aerospace industries, has scheduled a conference call for November 14, 2024, at 5:00pm ET to discuss first quarter fiscal year 2025 financial results. The company will release its financial results and file its 10-Q after market close on the same day. Interested parties can join via phone at (844) 735-3662 or (412) 317-5705, or through a live webcast. A replay will be available until November 21, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
conferences earnings
-
Rhea-AI Summary

Precision Optics (NASDAQ: POCI) announced that its customer, a surgical robotics company, received FDA 510(k) clearance for its AI-powered platform treating Benign Prostate Hyperplasia. POC designs and manufactures the single-use endoscope imaging assembly for this system. The company has begun production deliveries against a $9 million order, with estimated deliveries of $3.6 million during fiscal year ending June 2025. POC expects significant long-term growth as their customer deploys the new robotic system in the market where they already hold a dominant position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
-
Rhea-AI Summary

Precision Optics (Nasdaq: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, has announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. The company will engage in two key activities:

1. A webcast presentation scheduled for 1:15 pm ET, accessible via the conference homepage or a direct link.

2. Virtual one-on-one meetings with investors throughout the event.

Interested parties can access the webcast through the provided links, with a replay option available post-event. To arrange one-on-one meetings, investors can contact Lytham Partners directly or register for the event through the given link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags
conferences
Rhea-AI Summary

Precision Optics (NASDAQ: POCI) reported its Q4 and fiscal year 2024 results. FY 2024 revenue was $19.1 million, down from $21.0 million in FY 2023, but exceeding the high-end guidance. Production revenue decreased 25% to $10.8 million, while engineering revenue increased 24% to a record $8.3 million. The company reported a net loss of $3.0 million compared to a $0.1 million loss in the previous year.

For Q4 FY2024, revenue was $4.7 million, down from $5.0 million in Q4 FY2023. The company received a $9 million production order for a high-volume single-use cystoscopy surgery program in May 2024. Despite facing the loss of several significant programs, Precision Optics backfilled a portion of the shortfall with record product development revenue. The company expects double-digit revenue growth for fiscal 2025, with significant increases beginning in Q2 FY2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.99%
Tags

FAQ

What is the current stock price of Precision Optics (POCI)?

The current stock price of Precision Optics (POCI) is $4.83 as of July 3, 2025.

What is the market cap of Precision Optics (POCI)?

The market cap of Precision Optics (POCI) is approximately 35.0M.
Precision Optics

Nasdaq:POCI

POCI Rankings

POCI Stock Data

35.03M
6.25M
22.44%
25.56%
0.05%
Medical Instruments & Supplies
Electromedical & Electrotherapeutic Apparatus
Link
United States
GARDNER